| abstract |
The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlle d in vitro release of the active ingredient in phosphate buffer at pH 6.8 of n ot less than about 80 % after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of th e active moiety or moieties for 24 hours. The invention also relates to the us e of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders. |